Hodges Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Hodges Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-218,625	Closed	-$13.1M	–	266
2018 Q2	$13.1M	Sell	218,625 -57,050	-21%	-$2.96M	0.96%	28
2018 Q1	$12.6M	Sell	275,675 -28,320	-9%	-$1.18M	1%	28
2017 Q4	$12.1M	Sell	303,995 -24,950	-8%	-$986K	0.89%	37
2017 Q3	$13.2M	Sell	328,945 -70,595	-18%	-$3.06M	0.89%	39
2017 Q2	$17.2M	Buy	+399,540	New	+$14.2M	1.02%	33
2016 Q4	–	Sell	-8,900	Closed	-$220K	–	288
2016 Q3	$220K	Sell	8,900 -9,800	-52%	-$222K	0.01%	255
2016 Q2	$381K	Sell	18,700 -9,300	-33%	-$165K	0.02%	215
2016 Q1	$427K	Sell	28,000 -302,380	-92%	-$3.95M	0.02%	210
2015 Q4	$4.44M	Sell	330,380 -19,130	-5%	-$296K	0.18%	99
2015 Q3	$4.9M	Sell	349,510 -108,460	-24%	-$2.02M	0.2%	102
2015 Q2	$7.78M	Buy	+457,970	New	+$6.52M	0.28%	100

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Hodges Capital Management's SUPN Position: Q3 2018 in Review

Hodges Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 218,625 shares — an estimated $13.1M sold.

Hodges Capital Management first reported a position in SUPN in Q2 2015 and held it in 11 quarters. The position peaked at $17.2M in Q2 2017. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Hodges Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Hodges Capital Management sold 218,625 Supernus Pharmaceuticals shares in Q3 2018, an estimated $13.1M.
Hodges Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 11 quarters.
Hodges Capital Management's Supernus Pharmaceuticals position peaked at $17.2M in Q2 2017.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Hodges Capital Management's 13F filing for Q3 2018, filed 29 Oct 2018.